Xstelos Holdings (XTLS) Return on Assets ROA from the third quarter of 2013 to third quarter of 2012 and for the year 2013, Average High and Low, Fundamental Ratios from Sep 30 2013 to Sep 30 2012 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Xstelos Holdings, Inc.  (XTLS)


Xstelos Holdings's ROA from the third quarter of 2013 to the third quarter of 2012 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Xstelos Holdings's ROA in the third quarter of 2013?
Xstelos Holdings, Inc. achieved a return on average assets (ROA) of 12.69 % in its third quarter of 2013, which is below Xstelos Holdings's average return on assets, which stands at 21.9%.

ROA decreased relative to the period ending Jun 30 2013, due to the decline in net income.

However, within the Healthcare sector 59 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the second quarter of 2013 from 441 to 518.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2013)
III. Quarter		 (Jun 30 2013)
II. Quarter		 (Mar 31 2013)
I. Quarter		 (Dec 31 2012)
IV. Quarter		 (Sep 30 2012)
III. Quarter
Y / Y Total Assets Change -13.91 % 2.9 % 12.02 % - -
Y / Y Net Income Change -77.75 % -97.18 % - - -
Net Income (TTM) in million 14 16 34 36 23
Return On Assets (TTM) 12.69 % 13.57 % 29.42 % 32.2 % 27.23 %
XTLS's Total Ranking # 518 # 441 # 183 # 153 #
Total Assets (TTM) in million 108 111 113 114 126
Seq. Total Assets Change -2.65 % -1.88 % -0.83 % -9.11 % 16.35 %
Seq. Net Income Change -14.42 % - - 558.86 % -89.16 %

XTLS's 5 Years Annual ROA >> Back to XTLS Management Effectiveness >> Compare XTLS ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 16
Sector # 60
Overall # 408

Return On Assets Statistics
High Average Low
32.1 %
21.9 %
12.65 %
(Dec 31 2012)   (Sep 30 2013)





Financial Statements
Xstelos Holdings's Assets $ 108 million XTLS's Balance sheet
Xstelos Holdings's Income $ 0 million Quarterly XTLS's Income Statement
XTLS's Income by Division See XTLS's Income by Division



Annual Return On Assets (Dec 31 2012)
FY 2012
FY
FY
FY
FY
Y / Y Total Assets Change - - - - -
Total Assets in million 114 0 0 0 0
Y / Y Net Income Change - - - - -
Net Income in million 36 0 0 0 0
Annual Return On Assets 31.65 % - - - -

XTLS's 5 Years Annual ROA >> Back to XTLS Management Effectiveness >> Compare XTLS ROA to its Competitors



Comment on XTLS's ROA in the fiscal year ending 2012
In the fiscal year 2012 ROA improved to 31.65 % compared to prior year, due to annual net income growth of % to $36.15 million, while value of Xstelos Holdings's overall assets grew just by % to $114.23 million, compared to $114.23 a year before.


More Return On Assets Ratios
XTLS's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
XTLS's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for XTLS's Competitors
Subscribers only: Roa for Xstelos Holdings's Suppliers
Subscribers only: Return On Assets for XTLS's Customers

You may also want to know
XTLS's Roi XTLS's Inventory Turnover Ratio XTLS's Growth Rates XTLS's Dividend Comparisons
XTLS's Profitability Ratios XTLS's Asset Turnover Ratio XTLS's Dividend Growth
XTLS's Roe XTLS's Valuation Ratios XTLS's Financial Strength Ratios XTLS's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2013, within Healthcare Sector ROA
Regeneron Pharmaceuticals Inc   34.05 %
Acorda Therapeutics Inc   24.98 %
Cellular Biomedicine Group Inc   24.54 %
Biospecifics Technologies Corp  23.08 %
Myriad Genetics Inc   22.75 %
Meridian Bioscience Inc   22.67 %
Psychemedics Corporation  22.52 %
China Biologic Products Holdings Inc   21.81 %
Repligen Corp  20.18 %
Nutrastar International Inc.  20.15 %
Sunlink Health Systems Inc   19.41 %
Elite Pharmaceuticals Inc   18.21 %
Jazz Pharmaceuticals Plc  17.52 %
Edwards Lifesciences Corporation  17.34 %
United Therapeutics Corporation  17.02 %
Intuitive Surgical Inc   16.79 %
Mosaic Immunoengineering Inc   16.60 %
Abbvie Inc   16.46 %
Idexx Laboratories Inc  16.36 %
Biogen Inc   16.02 %
Atrion Corporation  15.62 %
Healthcare Services Group Inc   15.35 %
Encompass Health Corporation  15.24 %
Bio techne Corp  15.06 %
Waters Corporation  14.81 %
Nrc Health  14.74 %
Surmodics Inc   14.40 %
Mettler toledo International Inc   14.36 %
Addus Homecare Corp  14.36 %
Eli Lilly And Company  14.29 %

Date modified: -0001-11-30T00:00:00+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.